By NewsDesk @infectiousdiseasenews
Seqirus announced today that it has begun to ship its portfolio of innovative seasonal influenza vaccines across the U.S. in preparation for the 2021/22 influenza season. The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic, supplying approximately 60 million doses of influenza vaccines for healthcare providers across the U.S.
“We are proud to offer our portfolio of differentiated flu vaccines, including cell-based and adjuvanted vaccines that utilize innovative, proprietary technologies designed to address factors that may impact vaccine effectiveness,” said Dave Ross, Vice President, North America Commercial Operations at Seqirus. “Despite the immeasurable ways the world has changed in the last year, our mission for the upcoming influenza season hasn’t faltered. We are driven by our commitment to deliver safe and effective influenza vaccines to as many eligible people as possible, including vulnerable groups like young children and adults 65 years and older.”
Seqirus, the only global vaccine company with a singular focus on influenza, provides a portfolio of products that offer protection from influenza for people of all ages – from children as young as six months of age to adults 65 years and older – including:
- FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the first and only cell-based quadrivalent influenza vaccine for persons two years of age and older, and currently under review by the U.S. Food and Drug Administration (FDA) for an expanded age indication for children as young as six months of age;
- FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted), the first and only adjuvanted quadrivalent seasonal influenza vaccine for adults 65 and older; and
- AFLURIA® QUADRIVALENT (Influenza Vaccine), an egg-based quadrivalent influenza vaccine approved for use in eligible persons six months of age and older.
“A continued focus on influenza vaccination is critically important because, while rates of influenza were generally low last season, we cannot assume this will be the case during the coming year and we need to be prepared,” said Gregg Sylvester, MD, Chief Medical Officer at Seqirus. “With our rich history and exclusive focus on influenza, we know that influenza vaccination can save lives and is an important step we can take to help protect ourselves, our loved ones and our communities.”
- Plague vaccine: University of Oxford launches Phase 1 trial
- RSV outbreak in New Zealand
- Samoa reports rotavirus outbreak, 31 cases confirmed
- Philippines reports 55 additional Delta variant cases
- Shingles vaccine, Shingrix, gets FDA approval for prevention in immunocompromised adults
- Antibiotics: DALVANCE receives FDA approval
- Powassan virus: 2nd case reported in Maine in 2021
- Brazil yellow fever: Human death recorded in Amapá state, Monkey deaths in Santa Catarina
- Riyadh man is Saudi Arabia’s 10th MERS case of 2021
- Recovered COVID-19 patients retain broad and effective longer-term immunity to the disease: Emory study
One thought on “Flu vaccines: 60 million doses being shipped, according to Seqirus”
How absolutely wonderful! Influenza vaccines, but CDC said that there have been no cases of influenza since SARS-CoV 2 to over the limelight. So what to do with the 60 million doses?